ICP-B161 not checked
Beijing InnoCare Pharma Tech Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dose escalation in Part A will be conducted in 3 Cohorts (Cohorts 1 to 3). Eight participants will be enrolled in each cohort and randomized to receive either ICP-B161 or placebo (ratio 5:1). ICP-B161 will be administered to Cohort 1 participants at the starting dose of 150 mg sc and increased in each new group. Three nominal dose levels in the range of 150 mg sc to 900 mg iv have been selected…”In the company’s words, NCT07911982 on ClinicalTrials.gov
- Tested for
- Inflammatory Bowel Disease(IBD)
- Main trialPhase 1
- “This is a randomized, double-blind, placebo-controlled, ascending dose study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) followed by a multiple ascending dose (MAD) part (Part B). The decision to escalate between dose levels and proceed to Part B will be based upon review of blinded available safety data by a Safety Review Committee.”In the company’s words, NCT07911982 on ClinicalTrials.gov
Other drugs for Inflammatory Bowel Disease(IBD)
- ObefazimodAbivax S.A. · Phase 3
- TofacitinibPfizer · Phase 3
- RisankizumabAbbVie · Phase 3
- UpadacitinibAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
Coming up1
- Mar 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Mar 2028 | Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026